Cancer Biomarkers Market Size, Share, Future Analysis, 2026-2034

Market Overview

According to fortune business insights, the global cancer biomarkers market size was valued at USD 42.87 billion in 2025. The market is projected to grow from USD 48.2 billion in 2026 to USD 83.61 billion by 2034, exhibiting a CAGR of 7.13% during the forecast period. North America dominated the cancer biomarkers market with a market share of 35.94% in 2025.

The analysis shows that the rising prevalence of cancer globally is increasing the demand for early disease diagnosis, subsequently propelling market growth. The expanding use of biomarkers in drug discovery, development, and the shift toward personalized medicine are also key factors. This trend indicates a strong demand for cancer biomarkers worldwide.

Major Players Profiled in the Market Report:

• F. Hoffmann-La Roche Ltd.

• Abbott

• Thermo Fisher Scientific

• Bio-Rad Laboratories, Inc.

• CENTOGENE N.V.

• Axon Medchem

• Sino Biological Inc.

• R&D System

• BioVision Inc.

• Myriad RBM

Segments

Rising Prevalence to Propel Breast Cancer Segment GrowthBased on cancer type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. The breast cancer segment holds the largest market share, driven by the increasing prevalence of the disease and a rise in awareness about early diagnosis. This has led to a large patient pool undergoing diagnostic tests, supported by rising research activities focused on new biomarkers for breast cancer detection.

High Prevalence of Breast Cancer to Drive HER-2 Segment ExpansionBy biomarker type, the market is categorized into PSA, HER-2, EGFR, KRAS, and others. The HER-2 segment is leading the market, driven by the rising prevalence of breast cancer and increasing awareness about disease diagnosis in both developed and developing countries. The introduction of new HER-2-based tests, including liquid biopsy, is further propelling global demand.

New Product Introductions to Dominate the Diagnostics & Research Laboratories SegmentBased on end-user, the market is segmented into pharmaceutical & biotechnology companies, diagnostics & research laboratories, hospitals & specialty clinics, and others. The diagnostics & research laboratories segment holds the largest market share owing to the continuous introduction of new diagnostic products by key players. The growing importance of biomarker testing in disease diagnosis and research further solidifies this segment's dominance.

For detailed market insights: https://www.fortunebusinessinsights.com/industry-reports/cancer-biomarkers-market-100630

Drivers & Restraints

Rising Cancer Prevalence and Shift to Personalized Medicine to Propel Market GrowthThe rapid growth in the prevalence of cancer worldwide is a primary driver, increasing the demand for early and accurate diagnostic tools. Furthermore, a significant paradigm shift toward personalized medicine for cancer treatment is fueling the need for specific biomarkers to guide diagnosis, prognosis, and the selection of targeted therapies, boosting market growth.

However, the lack of reimbursement policies for biomarker tests in many emerging and developed countries may hamper market growth. Additionally, the high cost of cancer diagnosis and treatment can limit the number of patients undergoing biomarker testing, with some opting for lower-cost detection methods, which may restrain market expansion.

Regional Insights

Advanced Diagnostic Technologies in North America Propel Regional Market GrowthNorth America holds the dominant cancer biomarkers market share and is projected to maintain its lead during the forecast period. The region’s growth is attributed to the strong adoption of advanced technologies like next-generation sequencing, a well-established regulatory framework, high healthcare spending, and sustained investment in oncology research.

Asia Pacific is one of the fastest-growing regions in the market. The growth is attributed to the accelerating uptake of biomarker-based cancer diagnostics, evolving regulatory pathways that support faster approvals, and increasing public and private investment in oncology research in countries like China, Japan, and India.

Cancer Biomarkers Market Future Growth:

The cancer biomarkers market is experiencing robust growth, fueled by the rising global incidence of cancer, a paradigm shift toward personalized medicine, and rapid technological advancements in genomics and proteomics. Today's oncology care is increasingly reliant on biomarkers for early detection, accurate diagnosis, risk stratification, and monitoring treatment response. There is a strong trend toward non-invasive liquid biopsies and the discovery of novel biomarkers for targeted therapies and immunotherapy. The rapid expansion of companion diagnostics and increasing investment in drug discovery and development are also key growth drivers. While North America continues to dominate, the Asia-Pacific region is seeing a surge in demand, driven by improving healthcare infrastructure and rising awareness.

Competitive Landscape

Focus on Novel Product Launches and Strategic Acquisitions to Propel Market GrowthThe market features prominent players like F. Hoffmann-La Roche Ltd., Abbott, and Thermo Fisher Scientific. These leading companies are accelerating growth through strategic initiatives such as launching novel biomarker tests, entering into companion diagnostic agreements, and pursuing mergers and acquisitions. Their proactive approach to innovation and market expansion continues to fuel the market’s momentum.

Key Industry Developments

• March 2021: Roche received approval from the U.S. FDA for the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify cancer patients who can benefit from more effective, targeted treatment.